following a full submission
pazopanib (Votrient®) is accepted for restricted use within NHS Scotland.
Indication under review: First-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
SMC restriction: use is restricted to the first-line treatment of advanced RCC.
Pazopanib was superior to placebo for the primary endpoint, progression free survival, in the whole population and the treatment naïve and cytokine pre-treated sub-groups. An indirect comparison demonstrated that pazopanib had similar efficacy to the main comparator.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of pazopanib. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.
Download detailed advice122KB (PDF)
Medicine details
- Medicine name:
- pazopanib (Votrient)
- SMC ID:
- 676/11
- Indication:
- For the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 March 2011